Bolt Biotherapeutics, Inc. SEC filings BOLT

Bolt Biotherapeutics, Inc. has 294 filings in SEC EDGAR's recent list, going back to May 7, 2015. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (material agreement, agreement ended, acquisition or sale of assets, unregistered share sale, officer or director change, bylaw or fiscal year change, regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Form Description Filed Period
S-8 Employee stock plan registration Mar 12, 2026 —
S-8 Employee stock plan registration Mar 24, 2025 —
S-8 Employee stock plan registration Mar 21, 2024 —
S-8 Employee stock plan registration Mar 29, 2023 —
424B5 Prospectus supplement Apr 7, 2022 —
S-3 Shelf registration Mar 30, 2022 —
S-8 Employee stock plan registration Mar 30, 2022 —
S-8 Employee stock plan registration Feb 5, 2021 —
424B4 Prospectus Feb 5, 2021 —
S-1MEF Filing Feb 4, 2021 —
S-1/A Amended registration statement Feb 3, 2021 —
S-1/A Amended registration statement Feb 1, 2021 —
S-1 Registration statement Jan 15, 2021 —

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BOLT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Redwood City, CA
SEC filer status
, Emerging growth company
SEC CIK
1641281
Former names
Bolt Therapeutics, Inc. (until May 7, 2015)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.